• ,

Epilepsy Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Marinus Pharmaceuticals, Takeda, UCB Biopharma, Zynerba Pharma,

Epilepsy Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies - Marinus Pharmaceuticals, Takeda, UCB Biopharma, Zynerba Pharma,
DelveInsight’s “Epilepsy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Epilepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epilepsy pipeline products will significantly revolutionize the Epilepsy market dynamics.  

 

Epilepsy Overview

According to the National Institute of Neurological Disorders and Stroke (NINDS), epilepsies are a spectrum of brain disorders ranging from severe, life-threatening, and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness. 

The Epilepsy signs and symptoms include: temporary confusion, staring spell, uncontrollable jerking movements of the arms and legs, loss of consciousness or awareness and psychic symptoms.

 

Some of the key facts of the Epilepsy Market Report: 

  • The Epilepsy market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • Certain factors like age, family history, head injury, stroke, dementia and others may increase the risk of epilepsy 
  • Key Epilepsy Companies: Marinus Pharmaceuticals, Takeda, UCB Biopharma, Zynerba Pharma, Neurocrine Bioscience, Cerevel Therapeutics, PTC Therapeutics, and others
  • Key Epilepsy Therapies: Ganaxolone, Soticlestat, Staccato Alprazolam, Zygel, ACT-709478, NBI-827104, CVL-865, and others
  • The Epilepsy epidemiology based on gender analyzed that epilepsy is more prevalent among males than in females 

 

Get a Free sample for the Epilepsy Market Report 

 

Key benefits of the Epilepsy Market report:

  1. Epilepsy market report covers a descriptive overview and comprehensive insight of the Epilepsy Epidemiology and Epilepsy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Epilepsy market report provides insights on the current and emerging therapies.
  3. Epilepsy market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Epilepsy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Epilepsy market.

 

Discover more about therapies set to grab major Epilepsy market share @ Epilepsy market forecast 

 

Epilepsy Epidemiology Segmentation:

The Epilepsy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Epilepsy
  • Prevalent Cases of Epilepsy by severity
  • Gender-specific Prevalence of Epilepsy
  • Diagnosed Cases of Episodic and Chronic Epilepsy 

 

Epilepsy Market  

The dynamics of the Epilepsy market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Zygel, ACT-709478, and others during the forecasted period 2019-2032. 

 

Download the report to understand which factors are driving Epilepsy epidemiology trends @ Epilepsy Epidemiological Insights 

 

Epilepsy Market Drivers

  • Specialized multidisciplinary care
  • Constructive Efforts
  • Promising Emerging Epilepsy Therapies
  • Increase in Research and Development
  • Government Initiatives and Funding

 

Epilepsy Therapies and Key Companies

  • Ganaxolone: Marinus Pharmaceuticals
  • Soticlestat: Takeda
  • Staccato Alprazolam: UCB Biopharma
  • Zygel: Zynerba Pharma
  • ACT-709478/ NBI-827104: Neurocrine Bioscience
  • CVL-865: Cerevel Therapeutics
  • Vatiquinone: PTC Therapeutics

 

Scope of the Epilepsy Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Epilepsy Companies: Marinus Pharmaceuticals, Takeda, UCB Biopharma, Zynerba Pharma, Neurocrine Bioscience, Cerevel Therapeutics, PTC Therapeutics, and others
  • Key Epilepsy Therapies: Ganaxolone, Soticlestat, Staccato Alprazolam, Zygel, ACT-709478, NBI-827104, CVL-865, and others
  • Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies
  • Epilepsy Market Dynamics:  Epilepsy market drivers and Epilepsy market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Epilepsy Market Access and Reimbursement 

 

Epilepsy Market Barriers

  • Heterogeneity Barrier
  • Differential Epilepsy Diagnosis
  • Specialized multidisciplinary care
  • Increase in Research and Development
  • Government Initiatives and Funding
  • Epilepsy Therapeutic Barriers
  • Public Health Barriers
  • Challenges during Clinical Studies

 

Table of Contents 

1. Epilepsy Market Report Introduction

2. Executive Summary for Epilepsy

3. SWOT analysis of Epilepsy

4. Epilepsy Patient Share (%) Overview at a Glance

5. Epilepsy Market Overview at a Glance

6. Epilepsy Disease Background and Overview

7. Epilepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Epilepsy 

9. Epilepsy Current Treatment and Medical Practices

10. Epilepsy Unmet Needs

11. Epilepsy Emerging Therapies

12. Epilepsy Market Outlook

13. Country-Wise Epilepsy Market Analysis (2019–2032)

14. Epilepsy Market Access and Reimbursement of Therapies

15. Epilepsy Market Drivers

16. Epilepsy Market Barriers

17.  Epilepsy Appendix

18. Epilepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Epilepsy treatment, visit @ Epilepsy Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/